News
Is the Silver Price Preparing to Challenge Its Record High?
More
The United States is celebrating Thanksgiving, meaning trading activity across financial markets will be lower than usual today (and to some extent tomorrow).
By: Isabella
Posted on : Nov 28 2025
USDCAD Wave Analysis – 26 November 2025
More
USDCAD: ⬇️ Sell – USDCAD reversed from resistance area – Likely to fall to support level 1.3975 USDCAD currency pair recently reversed from resistance area between the pivotal resistance level 1.4125 (which has been reversing the price from April), upper.
By: Isabella
Posted on : Nov 27 2025
USD/CAD Price Outlook: Key Economic Reports in Focus
More
Introduction to USDCAD The USD/CAD currency pair, often known as the “Loonie,” shows the exchange rate between the United States dollar (USD) and the Canadian dollar (CAD). This pair is highly influenced by commodities, particularly oil, due to Canada’s status as a major oil exporter. Traders frequently monitor this currency pair to gauge economic health […]
The post USD/CAD Price Outlook: Key Economic Reports in Focus appeared first on UnitedPips Ltd.
By: Emily Carter
Posted on : Nov 25 2025
EUR/USD Weekly Outlook
More
EUR/USD’s extended decline last week suggests that rebound from 1.1467 has completed at 1.1655. More importantly fall from 1.1917 high is not complete. Initial bias stays on the downside this week for 1.1467 first. Firm break there will target 1.1390, and then 38.2% retracement of 1.0176 to 1.1917 at 1.1252. On the upside, above 1.1551 […]
The post EUR/USD Weekly Outlook appeared first on Action Forex.
By: Elizabeth Sterling
Posted on : Nov 23 2025
EUR/USD pressured as USD gains traction on uneven data and Fed divide
More
EUR/USD posts moderate losses during the North American session on Friday as the US Dollar (USD) holds firm after the release of mixed economic data and dovish comments by Federal Reserve (Fed) officials. The pair trades at 1.1504, down 0.20%, after hitting a two-week low of 1.1491.
By: Isabella
Posted on : Nov 22 2025
USD/JPY Mid-Day Outlook
More
Daily Pivots: (S1) 155.85; (P) 156.52; (R1) 157.82; More… Intraday bias in USD/JPY remains on the upside for 158.85 key structural resistance, and then 161.8% projection of 146.58 to 153.26 from 149.37 at 160.17. On the downside, below 156.45 minor support will turn intraday bias neutral and bring consolidations, before staging another rise. In the […]
The post USD/JPY Mid-Day Outlook appeared first on Action Forex.
By: Elizabeth Sterling
Posted on : Nov 21 2025
US 30 forecast: the index has entered a downtrend
More
After hitting its all-time high, the US 30 entered a correction phase, which turned into a downtrend. The US 30 forecast for today is negative.
US 30 forecast: key trading points
- Recent data: initial jobless claims in the US increased to 232 thousand
- Market impact: the data has a moderately positive effect on the equity market
US 30 fundamental analysis
US initial jobless claims increased to 232 thousand, above the forecast of 223 thousand and the previous reading of 219 thousand. This means more people applied for benefits for the first time, and the figure continues to rise gradually. It signals a slight cooling in the labour market: layoffs are becoming more frequent than analysts expected, even though the overall level remains low by historical standards.
For the US 30, which comprises a large share of industrial companies, financial institutions, and major consumer brands, the impact looks mixed. Many components of the index directly depend on the real economy – industrial production, heavy machinery, banking, and consumer goods. If the market interprets the increase in jobless claims as the beginning of a more notable economic slowdown, these sectors may come under pressure first, as their profits depend heavily on business activity and investment flows. In this case, the US 30 may react cautiously or even decline following the release.
US initial jobless claims: https://tradingeconomics.com/united-states/jobless-claimsUS 30 technical analysis
The US 30 index entered a downtrend after breaking below the 46,475.0 support level. A new resistance level formed at 48,460.0. Volatility remains elevated, so the trend may change in the short term. The nearest downside target lies at 45,195.0.
The US 30 price forecast considers the following scenarios:
- Pessimistic US 30 scenario: if the price consolidates below the previously breached support level at 46,475.0, the index could fall to 45,195.0
- Optimistic US 30 scenario: a breakout above the 48,460.0 resistance level could propel the index to 49,275.0
Summary
For the broader US equity market and the US 30, the current situation increases short-term caution, while also opening the possibility for softer interest rate conditions later on. The final reaction will depend on whether upcoming labour market reports confirm a weakening trend and how the Federal Reserve responds. From a technical perspective, the next downside target could be 46,475.0.
Open Account
By: John Matthews
Posted on : Nov 20 2025
How Professional Forex Traders Build Consistent Profits: A Proven Strategy for Retail Traders
More
Is forex trading profitable? Is forex trading profitable? Most retail traders dive into the forex market searching for the “perfect setup” or the next...
The post How Professional Forex Traders Build Consistent Profits: A Proven Strategy for Retail Traders appeared first on Forex Trading Forum.
By: Isabella
Posted on : Nov 19 2025
How to Identify and Trade a Liquidating Market: A Guide for Active Traders
More
Easy trades that pay well How to Identify and Trade a Liquidating Market Easy trades that pay well A liquidating market occurs when traders...
The post How to Identify and Trade a Liquidating Market: A Guide for Active Traders appeared first on Forex Trading Forum.
By: Noah
Posted on : Nov 15 2025
AI picks & shovels versus AI miners. Also: "Gimme a stimmie!"
More
Listen to the full episode now or follow the Saxo Market Call on your favorite podcast app.
Today’s Links
John’s The FX Trader from earlier today on all things G10 FX, today asking if AUD getting overbaked, among many subplots.
Ole’s latest crude oil market update - careful now, it is thoughtful and deeply researched.
FT catching up with the narrative on data center capacity possibly limiting further AI buildout rates, even if capex demands continued to skyrocket. Then again, JP Morgan is out with a big report talking up the great buildout of AI infrastructure, a capex event that will be “sustained and extraordinary”.
EndgameMacro weighs in on an interesting way to view crypto and why the US government tolerates and even co-opts it: - as a liquidity shock absorber that dampens the impact into other markets without really hitting the economy.
Oh, those Russians. An elite Russian unit is making life tougher for Ukrainian drone operators and their more limited resources. The arms and technology race in the war there is horrible and fascinating to follow.
Nuclear rockets? I did not know this was a thing… Actually an old idea - but may have to stay unmanned if ever developed.
Chart of the Day - Viking Therapeutics
In the September 3 edition of this substack, we called out Viking Therapeutics (below) as the chart of the day, a company with an obesity drug candidate, assuming it can bring it to market next year. The trigger for highlighting the company was mention that Druckenmiller’s family office had a large holding. Since that post (and news item), the company’s share price is up some 50%, yesterday testing above the prior 2025 high. Some of the recent upside may be on general strength in healthcare- and pharma-related names, as there is quite a rotation going on. Who knows, maybe there is further upside potential if a large drug company considers it imperative to have a GLP-1 drug, just like Pfizer snapped up Metsera at a huge premium to have a drug in the obesity market. But the risk may be that GLP-1 is a competitive space, especially once they all have pill versions of their drug, assuming none of them has a significant edge in effectiveness. The Novo Nordisk - Eli Lilly relative performance looks extreme, given that Wegovy is not that inferior to Eli Lilly’s drug, etc.
Questions and comments, please!
We invite you to send any questions and comments you might have for the podcast team. Whether feedback on the show's content, questions about specific topics, or requests for more focus on a given market area in an upcoming podcast, please get in touch at [email protected].By: Jaxon Maddox
Posted on : Nov 14 2025